Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN | P10599 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 10/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990302 | 0.88 | FPR2 (0.40) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL11576785 | 0.88 | FPR2 (0.41) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL18923160 | 0.85 | CYP1A2 (0.41) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL5088882 | 0.85 | CYP1A2 (0.41) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL10627595 | 0.83 | CYP1A2 (0.41) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL3588499 | 0.83 | FPR2 (0.43) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| Hydrochloric Acid SCHEMBL29272006 | 0.82 | CYP1A2 (0.40) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL31296113 | 0.82 | CYP1A2 (0.40) | TXNTXNRD1FPR2F2RL1CYP1A2 | |
| Hydrochloric Acid SCHEMBL29248987 | 0.80 | TXN (0.42) | TXNTXNRD1ALDH1A1SMN1; SMN2FPR2 | |
| SCHEMBL28391810 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2489667-B1 | Quinoxaline derivative | ASKA PHARM CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | OKADA MAKOTO (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-6025489-A | Tricyclic pteridinones and a process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0429149-B1 | Tricyclic pteridinones and a process for their preparation | BERLEX LAB (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5854419-A | Tricyclic pteridinones and a process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-29 | — | — | US | disclosed |
| US-5602252-A | Tricyclic pteridinones and a process for their preparation | BERLEX LABORATORIES, INC. | 1997-02-11 | — | — | US | disclosed |
| EP-0429149-A1 | Tricyclic pteridinones and a process for their preparation | BERLEX LABORATORIES, INC. (US) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | TXN 3938/4885TXNRD1 3857/4885ALDH1A1 2703/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TXN 1146/4885TXNRD1 1538/4885ALDH1A1 2962/4885 |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | PDE9A, ADCY9, PDE3A | TXN 1525/4885TXNRD1 543/4885ALDH1A1 858/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | TXN 1525/4885TXNRD1 543/4885ALDH1A1 858/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | TXN 3804/4885TXNRD1 4485/4885ALDH1A1 4577/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TXN 2310/4885TXNRD1 1868/4885ALDH1A1 3337/4885 |
| US-20080076740-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | TXN 3558/4885TXNRD1 3880/4885ALDH1A1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.